Celator Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPXX)

$30.24 0.00 (0.00 %)
(As of 01/19/2018 06:37 AM ET)
Previous Close$30.24
Today's Range$30.24 - $30.24
52-Week Range$1.12 - $30.36
Volume1,000 shs
Average Volume2.62 million shs
Market CapitalizationN/A
P/E Ratio-51.25
Dividend YieldN/A
BetaN/A

About Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals logoCelator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Receive CPXX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CPXX
CUSIPN/A
WebN/A
Phone+1-609-2430123

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-51.2542372881356
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.59)
Net IncomeN/A
Net MarginsN/A
Return on Equity-75.03%
Return on Assets-46.70%

Miscellaneous

EmployeesN/A
Outstanding Shares42,870,000

Celator Pharmaceuticals (NASDAQ:CPXX) Frequently Asked Questions

What is Celator Pharmaceuticals' stock symbol?

Celator Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPXX."

How were Celator Pharmaceuticals' earnings last quarter?

Celator Pharmaceuticals Inc (NASDAQ:CPXX) issued its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. View Celator Pharmaceuticals' Earnings History.

Who are some of Celator Pharmaceuticals' key competitors?

How do I buy Celator Pharmaceuticals stock?

Shares of Celator Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celator Pharmaceuticals' stock price today?

One share of Celator Pharmaceuticals stock can currently be purchased for approximately $30.24.

How can I contact Celator Pharmaceuticals?

Celator Pharmaceuticals' mailing address is 303b College Rd E, PRINCETON, NJ 08540-6608, United States. The company can be reached via phone at +1-609-2430123.


MarketBeat Community Rating for Celator Pharmaceuticals (CPXX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  142
MarketBeat's community ratings are surveys of what our community members think about Celator Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celator Pharmaceuticals (NASDAQ:CPXX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Celator Pharmaceuticals (NASDAQ:CPXX) Consensus Price Target History

Price Target History for Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals (NASDAQ:CPXX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
6/1/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Roth CapitalDowngradeBuy -> Neutral$30.25 -> $26.00N/AView Rating Details
3/15/2016HC WainwrightBoost Price TargetBuy$20.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Celator Pharmaceuticals (NASDAQ:CPXX) Earnings History and Estimates Chart

Earnings by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals (NASDAQ CPXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.15)($0.16)ViewListenView Earnings Details
3/21/2016Q4($0.12)($0.13)ViewN/AView Earnings Details
11/12/2015Q315($0.16)($0.15)ViewListenView Earnings Details
8/11/2015Q215($0.14)($0.15)ViewListenView Earnings Details
5/7/2015Q1 2015($0.14)($0.14)ViewN/AView Earnings Details
3/17/2015Q4 2014($0.16)($0.07)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.21)($0.21)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.20)($0.18)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.24)($0.16)ViewN/AView Earnings Details
3/24/2014Q4 13($0.15)($0.13)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.20)($0.14)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.20)($0.18)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.20)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Celator Pharmaceuticals (NASDAQ:CPXX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celator Pharmaceuticals (NASDAQ CPXX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)
Insider Trades by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals (NASDAQ CPXX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2015Scott D MorensteinDirectorBuy5,000$1.87$9,350.00View SEC Filing  
10/6/2015Scott Thomas JacksonCEOBuy14,450$1.74$25,143.0050,043View SEC Filing  
10/5/2015Fred M PowellCFOBuy13,700$1.78$24,386.0031,458View SEC Filing  
10/1/2015Life Sciences Gp Ll Valence IIinsiderBuy12,200$1.64$20,008.00171,986View SEC Filing  
11/18/2014Fred M PowellCFOBuy6,000$2.20$13,200.00View SEC Filing  
11/18/2014Michael R DoughertyDirectorBuy20,000$2.15$43,000.00View SEC Filing  
11/18/2014Scott Thomas JacksonCEOBuy10,000$2.20$22,000.00View SEC Filing  
5/15/2014Fred M PowellCFOBuy2,500$2.50$6,250.00View SEC Filing  
12/17/2013Fred M PowellCFOBuy2,500$3.50$8,750.00View SEC Filing  
12/17/2013Scott Thomas JacksonCEOBuy3,000$3.50$10,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celator Pharmaceuticals (NASDAQ CPXX) News Headlines

Source:

SEC Filings

Celator Pharmaceuticals (NASDAQ:CPXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celator Pharmaceuticals (NASDAQ:CPXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celator Pharmaceuticals (NASDAQ CPXX) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.